Provided by Tiger Fintech (Singapore) Pte. Ltd.

Chimerix

8.43
+0.0000
Post-market: 8.450.0200+0.24%19:55 EST
Volume:7.02M
Turnover:59.13M
Market Cap:758.16M
PE:-8.98
High:8.44
Open:8.42
Low:8.42
Close:8.43
Loading ...

Chimerix’s Strategic Progress and Upcoming Catalysts: A Promising Outlook for 2025

TIPRANKS
·
06 Feb

CMRX Stock Skyrockets in 3 Months: Here's What You Should Know

Zacks
·
31 Jan

Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium

GlobeNewswire
·
30 Jan

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
25 Jan

Here’s Why Chimerix, Inc. (CMRX) Is Skyrocketing

Insider Monkey
·
14 Jan

Chimerix to Speak Today at The White House Cancer Moonshot Forum

GlobeNewswire
·
13 Jan

Chimerix Receives ‘Buy’ Rating from Edward White on Promising Drug Development and Strong Financial Outlook

TIPRANKS
·
30 Dec 2024

Chimerix Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
30 Dec 2024

Promising Outlook for Chimerix: Strategic Developments and Financial Strength Justify Buy Rating

TIPRANKS
·
30 Dec 2024

Chimerix Seeks Accelerated FDA Approval for Experimental Tumor Drug

MT Newswires Live
·
30 Dec 2024

Chimerix Inc - Requests Priority Review for Nda

THOMSON REUTERS
·
30 Dec 2024

Chimerix Inc - Enters Credit Facility of up to $30 Million With Svb

THOMSON REUTERS
·
30 Dec 2024

Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients With Recurrent H3 K27m-Mutant Diffuse Glioma

THOMSON REUTERS
·
30 Dec 2024

Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

GlobeNewswire
·
30 Dec 2024

Chimerix Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Dec 2024

Edward White’s Buy Rating on Chimerix Driven by Promising Clinical Data and Strategic NDA Plans

TIPRANKS
·
11 Dec 2024